Attending LARC allows you to update your knowledge on the regulatory landscape in Latin America and is an opportunity to interact with regulatory agency officials and experts in the region.
Washington, DC (PRWEB) March 25, 2014
Twelve regulatory authorities from around the world will be among attendees discussing the opportunities provided by collaborating to achieve harmonization in regulation at the Latin American Regulatory Conference (LARC) 2014.
Global regulators, industry professionals and academia will gather at the event in Miami, Florida from May 14 to 15 to discuss the current regulatory landscape, future research and drug development in Latin America.
The main theme of this year’s conference will be “Growing Global Opportunities via Pharma-Co-Vergence in our Region”, highlighting the benefits of achieving pharmaceutical regulatory convergence through stakeholders’ collaboration.
Program Committee member Maria Guazzaroni Jacobs, PhD, Director of Quality and Regulatory Policy (QRP) for Pfizer Inc., US, said: “Attending LARC allows you to update your knowledge on the regulatory landscape in Latin America and is an opportunity to interact with regulatory agency officials and experts in the region.”
High profile presenters will include keynote speaker Ricardo Walter Rüttimann, Director of the Vaccines Division at Fighting Infectious Diseases in Emergent Countries (FIDEC-FUNCEI) in the US.
The meeting will also feature expert regulatory speakers including Patricia Aprea, MD, Head of the Biologics Products Department at ANMAT, who will give the Argentinian perspective on biotherapeutics and biosimilar products; Francisco Garcia Zetina, IQ, Director for COFEPRIS, who will give the Mexican perspective during the same session; and Guisela Zurich, QF, Head of ANAMED, who will give the Chilean perspective on the potential benefits and challenges of Multi-regional Clinical Trials (MRCTs).
Featured topics include:
•Regulatory Landscape and Regulatory Convergence Framework: Red PARF/ VII PANDRH Discussions
•New Regulatory Approaches and Initiatives
•Multi-regional Clinical Trials (MRCTs)
•Drug Safety, Marketing Surveillance, and Quality Control Monitoring
•Health Systems and Security of the Supply Chain: Traceability and Counterfeit Medicines
•Biologics and Biosimilars Regulations: Industry and Regulatory Agency Perspectives
For more information or to register visit http://www.diahome.org/LARC2014
To view a video interview with a previous attendee visit http://www.youtube.com/watch?v=6ZI3BeUYQAo
DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators and influencers to exchange knowledge and collaborate in an impartial setting. DIA’s network creates unparalleled opportunities for the exchange of knowledge and has the interdisciplinary experience to prepare for future developments.
The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications, and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients.
DIA is an independent, nonprofit organization headquartered in Washington, D.C., USA with regional offices covering North and South America (Horsham, Pennsylvania, USA); Europe, North Africa and the Middle East (Basel, Switzerland); Japan (Tokyo); India (Mumbai); and China (Beijing).